Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 45963-0454
Overview of the Drug
NDC 45963-0454 refers to Rucaparib, sold under the brand name Rubraca. Rucaparib is a poly ADP-ribose polymerase (PARP) inhibitor approved by the FDA for management of ovarian cancer, prostate cancer, and related indications.
Market Context
- Indications: Ovarian cancer (maintenance and recurrence), prostate cancer (metastatic castration-resistant forms).
- Competitive Landscape: Key competitors include olaparib (Lynparza) and niraparib (Zejula). These drugs similarly target homologous recombination repair pathways.
- Market Size: Estimated U.S. sales for PARP inhibitors reached approximately $3.2 billion in 2022, with Rucaparib accounting for roughly 20-25% of sales in this class.
Current Market Penetration
- Rucaparib is approved for maintenance therapy in ovarian cancer with recurrent disease and for treating metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations.
- It holds a smaller share compared to olaparib based on sales data, but usage is growing, especially in ovarian indications following positive trial results.
Pricing and Reimbursement
- Average Wholesale Price (AWP): Approximately $12,900 per 30-day supply; actual reimbursed prices vary based on payers.
- Average Selling Price (ASP): Estimated at $11,100 per month, reflecting negotiated discounts and rebates.
- Insurance Coverage: Widely covered under Medicare, Medicaid, and private insurance, with patient co-pays depending on formulary tier.
Price Trends and Projections
| Year |
Estimated Average Monthly Price |
Notes |
| 2022 |
$11,100 |
Current pricing, stable with minor discounts |
| 2023 |
$10,900 - $11,200 |
Slight decline due to increased competition |
| 2024 |
$10,700 - $11,000 |
Anticipated stabilization or slight decrease |
| 2025 |
$10,500 - $10,800 |
Competition and biosimilars could drive further reductions |
Projection base: Assumes no major regulatory changes or patent expirations before 2025. Market competition, including generic or biosimilar entries, could accelerate price drops post-exclusivity.
Regulatory and Patent Outlook
- Patent protections for Rubraca extend into late 2020s, with exclusivity potentially until 2027-2029.
- No biosimilar or generic versions are currently approved, limiting downward price pressures in the near term.
Revenue Outlook
- Global sales are projected to increase from approximately $650 million in 2022 to over $1 billion by 2025.
- U.S. sales are expected to constitute roughly 60-70% of this total.
Key Factors Influencing Price and Market Growth
- Clinical Data: New trial results could expand or limit indications.
- Market Penetration: Increased use in prostate and other solid tumors.
- Pricing Policies: Rising emphasis on value-based pricing could affect margins.
Summary
Rucaparib (NDC 45963-0454) operates in a competitive PARP inhibitor market, with stable prices around $11,000 per month, gradually decreasing due to competition and market maturation. Revenue growth remains steady through broader indication approval and usage.
Key Takeaways
- The drug’s U.S. market value is approximately $230 million annually.
- Price projections suggest a slight decrease over the next two years, driven primarily by market competition.
- Patent and exclusivity protections limit generic entry until 2027–2029.
- Growing indications and clinical data may sustain or increase demand.
FAQs
1. When do biosimilars or generics for Rucaparib potentially enter the market?
Post-patent expiration in late 2020s; exact timing depends on patent litigation and regulatory approvals.
2. How does Rucaparib compare price-wise to other PARP inhibitors?
It generally costs slightly more than niraparib but less than olaparib, factoring in negotiated discounts.
3. What are the primary factors affecting Rucaparib sales growth?
Indication expansion, clinical trial outcomes, and competitive dynamics.
4. Are there upcoming regulatory changes that could impact pricing?
Possible adjustments due to value-based pricing policies, but no immediate regulatory disruptions expected.
5. How do reimbursement rates influence actual patient access?
Reimbursement variability and patient co-pays can limit access despite favorable list prices.
References
- IQVIA. "Pharma Market Outlook 2022."
- FDA. "Rubraca (Rucaparib) Prescribing Information."
- Evaluate Pharma. "PARP Inhibitors Market Report," 2023.
- CMS. "Medicare Part B and Part D Drug Reimbursement Policies."
- Centers for Disease Control and Prevention. "Ovarian Cancer Statistics," 2022.
